SURPASS–CVOT (Recruiting)

Double-blind study comparing Tirzepatide (up to 15mg) to placebo on Major Cardiovascular events, when added to glucose-lowering regimen and other standard of care (e.g. beta blockers, aspirin, ace inhibitors, statins), in patients with T2DM and with established CV disease